Abstract:Background: Despite widespread use of fecal immunochemical tests (FITs) for colorectal cancer (CRC) screening, data to guide test selection are limited. Objective: To compare the performance characteristics of 5 commonly used FITs, using colonoscopy as the reference standard. Design: Cross-sectional study. (ClinicalTrials.gov: NCT03264898). Setting: Three U.S. academic medical centers and affiliated endoscopy units. Participants: Patients aged 50 to 85 years undergoing screening or surveillance colonoscopy. Intervention: Participants completed 5 different FITs before their colonoscopy, including 4 qualitative tests (Hemoccult ICT, Hemosure iFOB, OC-Light S FIT, QuickVue iFOB) and 1 quantitative test (OC-Auto FIT, which was run at the manufacturer's threshold for positivity of >100 ng/mL). Measurements: The primary outcome was test performance (sensitivity and specificity) for each of the 5 FITs for advanced colorectal neoplasia (ACN), defined as advanced polyps or CRC. Positivity rates, positive and negative predictive values, and rates of unevaluable tests were compared. Multivariable models were used to identify factors affecting sensitivity. Results: A total of 3761 participants were enrolled, with a mean age of 62.1 years (SD, 7.8); 63.2% of participants were female, 5.7% were Black, 86.4% were White, and 28.7% were Hispanic. There were 320 participants with ACN (8.5%), including 9 with CRC (0.2%). The test positivity rate varied 4-fold (3.9% to 16.4%) across FITs. Rates of unevaluable FITs ranged from 0.2% to 2.5%. The sensitivity for ACN varied from 10.1% to 36.7%, and specificity varied from 85.5% to 96.6%. Differences in sensitivity between FITs were all statistically significantly different except between Hemosure iFOB and QuickVue iFOB, and specificity differences were all statistically significantly different from one another. In addition to FIT brand, distal location of ACN was also associated with higher FIT sensitivity. Limitation: The study did not assess the programmatic sensitivity of annual FIT. Conclusion: Although considered a single class, FITs have varying test performance for detecting ACN and should not be considered interchangeable. Primary funding source: National Institutes of Health.

Predictive Modeling of Colonoscopic Findings in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program

Risk-stratified selection to colonoscopy in FIT colorectal cancer screening: development and temporal validation of a prediction model

A Validated Tool of Combining Risk Factors with Fecal Immunochemical Test for Selecting Colonoscopy in Asymptomatic Chinese Population

Yield and Effectiveness of 2-Sample Fecal Immunochemical Test-Based Screening Program for Colorectal Cancer.

Estimate of Increase in Colorectal Cancer Diagnoses with Expansion of Fecal Immunochemical Testing in an Urban Safety-Net Population

Predicting the Risk for Colorectal Cancer with Personal Characteristics and Fecal Immunochemical Test.

COLOFIT: Development and internal-external validation of models using age, sex, faecal immunochemical and blood tests to optimise diagnosis of colorectal cancer in symptomatic patients

Positive predictive values of fecal immunochemical tests used in the STOP CRC pragmatic trial

Faecal Immunochemical Testing in Symptomatic Primary Care Patients: A Diagnostic Accuracy Study

Up to 9 Rounds of Fecal Immunochemical Test (FIT) Enhanced Interpretation of Positive and Negative for Colorectal Cancer Screening

Diagnostic Performance of Faecal Immunochemical Testing (FIT) in Patients with Lynch Syndrome Scheduled for Colonoscopic Surveillance

Fecal Immunochemical Test To Detect Colorectal Neoplasia In Lynch Syndrome – A Prospective Multicenter Study

Strong Subsite-Specific Variation in Detecting Advanced Adenomas by Fecal Immunochemical Testing for Hemoglobin.

Low Rate of Cancer Detection by Colonoscopy in Asymptomatic, Average-Risk Subjects with Negative Results From Fecal Immunochemical Tests

Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia

Risk Scoring Systems for Predicting the Presence of Colorectal Neoplasia by Fecal Immunochemical Test Results in Chinese Population

Leveraging Fecal Microbial Markers to Improve the Diagnostic Accuracy of the Fecal Immunochemical Test for Advanced Colorectal Adenoma

Findings in the distal and proximal colon in colonoscopy screening after positive FIT and related pre-procedure factors

Risk Stratification of Symptomatic Patients Suspected of Colorectal Cancer Using Faecal and Urinary Markers.

Diagnostic accuracy of faecal immunochemical test for screening individuals with a family history of colorectal cancer.

Comparative Performance of Common Fecal Immunochemical Tests : A Cross-Sectional Study